Overview

Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)

Status:
Active, not recruiting

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

The study is a prospective, phase II trial single arm, historical control aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L(P) System, in combination with sorafenib in patient with advanced HCC. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

Phase:

Phase 2

Details

Lead Sponsor:

NovoCure GmbH
NovoCure Ltd.

Treatments:

Niacinamide
Sorafenib